The warrant exercise removes near-term dilution overhang and provides a cash cushion ahead of the Phase III MAVERIC readout, a binary catalyst. Traders should watch for any insider or institutional warrant exercise patterns before the October 16 expiry, as the remaining 425,000 warrants could add modest dilution if exercised.
Price Chart
Executive Summary
Cardiol Therapeutics announced receipt of over USD $7 million from the exercise of common share purchase warrants, extending its cash runway into H1 2028 and funding operations through the pivotal Phase III MAVERIC trial data readout in recurrent pericarditis. The company also accelerated the remaining 425,000 warrants (potential additional proceeds of USD $573,750), which will expire on October 16, 2026 if unexercised.
Key Facts
- Received over USD $7 million in proceeds from warrant exercises
- Cash runway extended into H1 2028
- Funds operations through pivotal Phase III MAVERIC trial topline data readout
- 425,000 warrants remain unexercised, representing potential additional gross proceeds of USD $573,750
- Warrants expire on October 16, 2026 if not exercised
- Originally 5,712,500 warrants issued in October 2025 private placement
Financial Impact
Over USD $7 million in cash proceeds from warrant exercises, with potential additional USD $573,750 from remaining 425,000 warrants
Risk Factors
- Phase III MAVERIC trial may fail to meet endpoints, wiping out pipeline value
- Remaining 425,000 warrants could still be exercised, adding modest dilution
- Cash runway only extends to H1 2028 — additional financing may be needed if MAVERIC readout is delayed or negative
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000889 |
| Document: cardiol6k.htm | 0001279569-26-000889 |
| Document: 0001279569-26-000889-index-headers.html | 0001279569-26-000889 |
| Document: 0001279569-26-000889-index.html | 0001279569-26-000889 |
| Document: 0001279569-26-000889.txt | 0001279569-26-000889 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.12 (−36.72%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.12 (−36.72%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.12 (−41.05%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.12 (−43.86%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.12 (−43.86%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.12 (−50.98%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.12 (−16.42%) |
Jul 14, 2026 15w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.12 (−2.61%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.12 (+12.90%) |
May 26, 2026 21w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.12 (−13.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers